NCT07185633View on ClinicalTrials.gov

Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2027

Conditions

aGVHD

Interventions

DRUG

Gecacitinib-Corticosteroid

Gecacitinib po. 50mg bid at least 28 days

DRUG

Methylprednisolone sodium succinate

Methylprednisolone sodium succinate IV 2mg/kg/d.

All Listed Sponsors

lead

Bin Gu

OTHER